Fiche du document
30 septembre 2021
- doi: 10.1093/jbcr/irab080
- issn: 1559-047X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1093/jbcr/irab080
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/33970273
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1559-0488
Ce document est lié à :
info:eu-repo/grantAgreement/EC/H2020/833594///
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_2FE6653546511
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Care and treatment AdministrationCiter ce document
M. Chemali et al., « Burn Center Organization and Cellular Therapy Integration: Managing Risks and Costs. », Serveur académique Lausannois, ID : 10.1093/jbcr/irab080
Métriques
Partage / Export
Résumé
The complex management of severe burn victims requires an integrative collaboration of multidisciplinary specialists in order to ensure quality and excellence in healthcare. This multidisciplinary care has quickly led to the integration of cell therapies in clinical care of burn patients. Specific advances in cellular therapy together with medical care have allowed for rapid treatment, shorter residence in hospitals and intensive care units, shorter durations of mechanical ventilation, lower complications and surgery interventions, and decreasing mortality rates. However, naturally fluctuating patient admission rates increase pressure toward optimized resource utilization. Besides, European translational developments of cellular therapies currently face potentially jeopardizing challenges on the policy front. The aim of the present work is to provide key considerations in burn care with focus on architectural and organizational aspects of burn centers, management of cellular therapy products, and guidelines in evolving restrictive regulations relative to standardized cell therapies. Thus, based on our experience, we present herein integrated management of risks and costs for preserving and optimizing clinical care and cellular therapies for patients in dire need.
